Cargando…
Burden of asthma with elevated blood eosinophil levels
BACKGROUND: Asthma is a common chronic condition with an economic burden of almost $56 billion annually in the US. Biologic markers like blood eosinophils, that help predict the risk of exacerbation could help guide more optimal treatment plans and reduce cost. The purpose of this study was to deter...
Autores principales: | Casciano, Julian, Krishnan, Jerry A., Small, Mary Buatti, Buck, Philip O., Gopalan, Gokul, Li, Chenghui, Kemp, Robert, Dotiwala, Zenobia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944449/ https://www.ncbi.nlm.nih.gov/pubmed/27412347 http://dx.doi.org/10.1186/s12890-016-0263-8 |
Ejemplares similares
-
Value of peripheral blood eosinophil markers to predict severity of asthma
por: Casciano, Julian, et al.
Publicado: (2016) -
The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective
por: Casciano, Julian P., et al.
Publicado: (2013) -
Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study
por: Kerkhof, Marjan, et al.
Publicado: (2018) -
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
por: McAllister, Peter, et al.
Publicado: (2021) -
Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)